Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Emergent BioSolutions Inc.NYSE: EBS

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $57.1M fell 15.9% year over year, ahead of the -49.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at -28.0% a year.

Context

  • Operating expenses amounted to 32.4% of revenue in FY2025, down 14.0 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -15.9% holds above the trailing-twelve-month pace of -49.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.1M-9.7% QoQ
Last fiscal yearDec 2025
$240.4M-50.3% YoY
LTMMar 2026
$229.6M-49.2% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.9%——
1 year-50.3%——
3-year CAGR-28.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
240.4M USD
Year-over-year change
-50.3%
4-year CAGR
-14.6%

Operating Expenses vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -49.2% is the lowest of 11, against a peer median of +4.0%.
  • Operating expenses amounts to 33.9% of revenue for EBS, versus a peer median of 51.8%.
EBS Competitors
Operating Expenses for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$350.61M USD-4.1%+4.5%68.3%
SNDLSNDL Inc.LTM Mar 2026CA$262.24M CAD-26.0%-18.6%28.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$229.6M USD-49.2%-28.0%33.9%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$201.51M USD+41.1%+18.6%—
ESPREsperion Therapeutics, Inc.LTM Mar 2026$196.07M USD-6.4%-2.1%46.9%
CMPSCOMPASS Pathways plcLTM Mar 2026$172.25M USD-9.0%+17.5%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$155.37M USD+12.5%-5.0%51.8%
PRTAProthena Corporation plcLTM Mar 2026$153.42M USD-44.5%+0.9%264.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$87.79M USD+12.2%+11.3%174.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$47.9M USD+53.4%+9.6%—
SIGASIGA Technologies, Inc.LTM Mar 2026$40.65M USD+14.0%-10.6%43.3%
Peer median (excluding EBS) —+4.0%+2.7%51.8%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.